Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2019-10-30 Capital/Financing Update
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Appendix 3B 14 pages 132.9KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) announcement used to notify the market of a new issue of securities, specifically a pro-rata non-renounceable entitlement offer of fully paid ordinary shares. It details the number of shares to be issued, issue price, purpose, and other terms related to the capital raising. The document is regulatory in nature, focused on capital issuance and quotation application rather than financial results or management commentary. It is not a full financial report, earnings release, or management discussion. It is a formal announcement of a capital raising event and related securities issuance, fitting the definition of a Capital/Financing Update.
2019-10-30 English
Notice Under Section 708AA 4 pages 39.4KB
Capital/Financing Update Classification · 95% confidence The document is a cleansing notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth) related to an accelerated non-renounceable entitlement offer by Phylogica Limited. It details the background of the entitlement offer, the underwriting arrangements, potential effects on control of the company, and compliance with relevant legislation. The document is a regulatory announcement about a capital raising event, specifically an entitlement offer, and includes legal and compliance disclosures. It does not contain financial statements or detailed financial performance data, nor is it a full report or presentation. It is an announcement related to financing activities and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (8679 characters) and content support this classification with high confidence.
2019-10-30 English
Entitlement Offer - Investor Presentation 27 pages 889.4KB
Investor Presentation Classification · 95% confidence The document is titled 'Entitlement offer – Investor Presentation October 2019' and contains detailed information about a proposed entitlement offer, including offer structure, use of funds, timelines, financial snapshot, and corporate overview. It is clearly a presentation aimed at investors to inform them about the capital raising event and the company's strategy and financial position related to this offer. There are no full financial statements or comprehensive financial reports typical of annual or interim reports. The document is not a regulatory announcement or a brief notice but a detailed presentation. Therefore, it fits the category of an Investor Presentation (IP). The document length (15,000 characters) and content support this classification with high confidence.
2019-10-30 English
Sept 2019 Quarterly Shareholder Update and Appendix 4C 8 pages 151.9KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 30 October 2019 titled 'Quarterly Shareholder Update' for Phylogica Limited (PYC Therapeutics). It discusses the company's progress and milestones in the third quarter of 2019, including drug development updates and strategic partnerships. Importantly, the document includes an Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B, which contains detailed financial data such as consolidated cash flow statements for the quarter ended 30 September 2019. The presence of substantive financial statements and analysis for a quarter period indicates this is a comprehensive interim/quarterly financial report rather than a brief announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2019
2019-10-29 English
Coprporate Governance Statement 17 pages 135.0KB
Governance Information Classification · 95% confidence The document is titled 'Corporate Governance Statement' and discusses the company's corporate governance policies, board responsibilities, audit committee, diversity policy, and compliance with ASX Corporate Governance Council Principles and Recommendations. It includes detailed governance practices and explanations of compliance with governance recommendations. There is no indication that this is an announcement or a brief summary; rather, it is a detailed governance report. This matches the description of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (15,000 characters) supports it being a full report rather than a brief announcement or notice.
2019-10-20 English
Notice of Annual General Meeting/Proxy Form 19 pages 274.0KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT' for Phylogica Limited, detailing the time, place, agenda, and resolutions for the AGM scheduled on 21 November 2019. It includes information on voting procedures, proxy forms, and explanatory notes on resolutions such as adoption of the Remuneration Report, election and re-election of directors, approval of placement capacity, and change of company name. The document explicitly states it is a Notice of AGM and Explanatory Statement, which are materials provided to shareholders ahead of the meeting to inform them and solicit votes. It does not contain the actual annual report, financial statements, or audit reports but references these reports as available on the company's website. The document is comprehensive and exceeds 5,000 characters, consistent with detailed AGM materials. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting.
2019-10-17 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.